DWK-1339 (MDR-1339) (Synonyms: MDR-1339) |
Catalog No.GC31083 |
DWK-1339 (MDR-1339) (DWK-1339) es un inhibidor de la agregaciÓn Aβ permeable a la barrera hematoencefÁlica y activo por vÍa oral, utilizado en la investigaciÓn de la enfermedad de Alzheimer'.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1018946-38-7
Sample solution is provided at 25 µL, 10mM.
DWK-1339 is an orally active and blood-brain-barrier-permeable Aβ-aggregation inhibitor, used in the research of Alzheimer's disease.
DWK-1339 (MDR-1339) is an Aβ-aggregation inhibitor, and shows no significant inhibition a panel of CYP isozymes, while it slightly inhibits CYP2C8 (IC50, 31.4 μM). DWK-1339 (3.1-50 μM) dose-dependently blocks the formation of Aβ aggregates, and disaggregates Aβ fibrils. DWK-1339 (1.5-10 μM) also protects cells from this Aβ-induced toxicity[1].
DWK-1339 (0.1-10 mg/kg, p.o.) dose-dependently restores the passive avoidance responses in mice models of Alzheimer's disease (AD), with an ED50 of 0.19 mg/kg. DWK-1339 (30 and 100 mg/kg, p.o. daily for 8 weeks) significantly improves spontaneous alternation, and reduces the Aβ1-40 and Aβ1-42 levels in APP/PS1 mice[1].
[1]. Ha HJ, et al. Discovery of an Orally Bioavailable Benzofuran Analogue That Serves as a β-Amyloid Aggregation Inhibitor for the Potential Treatment of Alzheimer's Disease. J Med Chem. 2018 Jan 11;61(1):396-402.
Average Rating: 5
(Based on Reviews and 18 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *